Based on this study, it is proposed that IbMADS1 is an important integrator at the initiation of tuberization. As a result, the initiation and development of tuberous roots seems to be well regulated by a network involving a MADS-box gene in which such hormones as jasmonic acid and cytokinins may act as trigger factors.
To the Editor, Recently, the associations between COVID-19 and its comorbidities including hypertension, diabetes, obesity, cardiovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, immunosuppression and other diseases have been reported in the many studies. 1 However, there is no clear evidence about whether patients with asthma were at a higher risk of severe or fatal COVID-19. Respiratory viral infections are one of the most common triggers for asthma exacerbations. Some studies have provided data about the prevalence of asthma in severe or fatal COVID-19 patients. 2-5 Higher levels of evidence are required to investigate the association between severe or fatal COVID-19 and asthma. Thus, we performed this systematic review and meta-analysis.
The dipole and quadrupole polarizabilities (both static and dynamic) of negatively charged helium‐like ions are investigated. The mass dependence of the polarizability is studied by changing the mass of the positively charged particle from one unit of electron mass to infinitely heavy. The calculations are carried out in the framework of the pseudostate summation method using exponential correlated wave functions having pseudorandomly generated nonlinear variational parameters. The dipole and quadrupole polarizabilities in terms of frequency and nuclear mass are reported for the first time. The effect of screened Coulomb potentials on the polarizabilities of D–, T–, 1H–,Pi–, Mu–, and Ps– are also presented.
BackgroundTo determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies.MethodsThe retrospective analysis includes clinical information from 767 patients with cancer treated at Hunan Cancer Hospital from 2017 to 2020. The pharmacovigilance data analysis includes individual cases of 38,705 safety reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2014 to 2020, and 25,122 cases of safety reports from the World Health Organization database VigiBase from 2014 to 2019. All cases that received anti-PD-1/PD-L1 treatment were included. Multiomics data from patients across 25 cancer types were download from The Cancer Genome Atlas. Logistic regression and propensity score algorithm was employed to calculate OR of irAEs.ResultsRetrospective analysis of in-house patients showed that irAE potential risks are higher in all cancer (OR 2.12, 95% CI 1.38 to 3.22, false discovery rate (FDR) adjusted-p=1.93×10−3) and patients with lung cancer (OR 3.16, 95% CI 1.67 to 5.95, FDR adjusted-p=1.93×10−3) when using antibiotics. Potential risk of irAEs in patients with lung cancer with antibiotic treatment is significantly higher in FAERS (OR 1.39, 95% CI 1.21 to 1.59; FDR adjusted-p=1.62×10−5) and VigiBase (OR 1.32, 95% CI 1.09 to 1.59, FDR adjusted-p=0.05). Mechanistically, decreased microbial diversity caused by antibiotics use may increase the irAE risk through mediating the irAE-related factors.ConclusionsOur study is the first to comprehensively demonstrate the associations of irAEs and antibiotic during anti-PD-1/PD-L1 therapy across a wide spectrum of cancers by analyzing multisource data. Administration of antibiotics should be carefully evaluated in patients with cancer treated by anti-PD-1/PD-L1 to avoid potentially increasing irAE risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.